Xenon Pharmaceuticals Inc. (XENE)

Market Cap	3.26B
Revenue (ttm)	7.50M
Net Income (ttm)	-306.33M
Shares Out	77.28M
EPS (ttm)	-3.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,275,632
Open	41.29
Previous Close	41.00
Day's Range	40.81 - 42.75
52-Week Range	26.74 - 46.60
Beta	0.98
Analysts	Strong Buy
Price Target	54.09 (+28.05%)
Earnings Date	Feb 26, 2026

About XENE

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The com...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 5, 2014
• Employees: 327
• Stock Exchange: NASDAQ
• Ticker Symbol: XENE
• Website: https://www.xenon-pharma.com

Analyst Summary

According to 11 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price target is $54.09, which is an increase of 28.05% from the latest price.

Price Target

$54.09

(28.05% upside)

Analyst Consensus: Strong Buy